<DOC>
	<DOCNO>NCT02043145</DOCNO>
	<brief_summary>This post marketing surveillance study Korea evaluate safety efficacy BOTOX ( botulinum toxin Type A ) patient receive treatment accord standard care primary axillary hyperhidrosis , focal spasticity moderate severe glabellar line clinical practice .</brief_summary>
	<brief_title>Safety Efficacy BOTOX® ( Botulinum Toxin Type A ) Korea</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients treat BOTOX® ( botulinum toxin Type A ) prescribe accord standard care clinical practice primary axillary hyperhidrosis , focal spasticity moderate severe glabellar line .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>